Drug Discovery용 AI 시장 규모, 점유율, 동향 분석 보고서 : 용도별, 치료 영역별, 최종 용도별, 지역별, 부문별 예측(2026-2033년)

Artificial Intelligence In Drug Discovery Market Summary

The global artificial intelligence in drug discovery market size was estimated at USD 2.35 billion in 2025 and is projected to reach USD 13.77 billion by 2033, growing at a CAGR of 24.8% from 2026 to 2033. The rising demand for cost-effective drug development, the increasing number of clinical trials in drug repurposing, and the growing prevalence of chronic diseases are significant factors contributing to market growth.

In addition, the growing focus on precision medicine and targeted drug development, as well as improvements in computing power and cloud infrastructure, are other factors fueling market growth. The rising demand for cost-effective drug development strategies substantially drives the growth of artificial intelligence (AI) in the drug discovery industry. According to an article published in the Frontiers in Pharmacology Journal in October 2025, Traditional drug discovery involves lengthy timelines, often exceeding a decade, and costs frequently exceed USD 2 billion per drug. AI in drug discovery and repurposing offers a strategy to bypass early-stage safety testing by focusing on approved or investigational drugs for new indications. Drug repurposing is anticipated to reduce risks and bring drugs to the market in 3-12 years, with an average investment of USD 300 million.

AI accelerates this process by rapidly analyzing extensive biological, chemical, and clinical datasets to identify novel associations between drugs and diseases. This reduces development timelines and costs, offering pharmaceutical companies and healthcare providers an economically viable alternative to the development of new drugs. Integrating artificial intelligence with drug repurposing effectively addresses key industry challenges by enhancing productivity while reducing associated risks and investments. AI enhances this economic advantage by efficiently analyzing extensive chemical libraries, biomedical literature, omics datasets, and real-world evidence to identify a limited set of high-probability candidates, rather than supporting broad empirical screening.

Global Artificial Intelligence In Drug Discovery Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global artificial intelligence in drug discovery market report based on application, therapeutic area, end use, and region.

• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Drug optimization and repurposing
• Preclinical testing
• Others
• Therapeutic Area Outlook (Revenue, USD Million, 2021 - 2033)
• Oncology
• Neurodegenerative Diseases
• Cardiovascular Disease
• Metabolic Diseases
• Infectious Disease
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations (CROs)
• Academic & Research Institutes
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• MEA
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
  • 1.2.1. Application Segment
  • 1.2.2. Therapeutic Area
  • 1.2.3. End Use
• 1.3. Information analysis
  • 1.3.1. Market formulation & data visualization
• 1.4. Data validation & publishing
• 1.5. Information Procurement
  • 1.5.1. Primary Research
• 1.6. Information or Data Analysis
• 1.7. Market Formulation & Validation
• 1.8. Market Model
• 1.9. Total Market: CAGR Calculation
• 1.10. Objectives
  • 1.10.1. Objective 1
  • 1.10.2. Objective 2

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Insights Landscape

Chapter 3. Artificial Intelligence in Drug Discovery Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising demand for cost-effective drug development
    • 3.2.1.2. Increasing clinical trials in drug repurposing
    • 3.2.1.3. Growing focus on precision medicine and targeted drug development
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Highly regulated industry
    • 3.2.2.2. High computational costs and infrastructure requirements
  • 3.2.3. Market opportunity analysis
  • 3.2.4. Market challenges analysis
• 3.3. Case Study Insights
• 3.4. Artificial Intelligence in Drug Discovery Market Analysis Tools
  • 3.4.1. Industry Analysis - Porter's
    • 3.4.1.1. Supplier power
    • 3.4.1.2. Buyer power
    • 3.4.1.3. Substitution threat
    • 3.4.1.4. Threat of new entrant
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political landscape
    • 3.4.2.2. Technological landscape
    • 3.4.2.3. Economic landscape
    • 3.4.2.4. Environmental Landscape
    • 3.4.2.5. Legal Landscape
    • 3.4.2.6. Social Landscape

Chapter 4. Artificial Intelligence in Drug Discovery Market: Application Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Artificial Intelligence in Drug Discovery Market Application Movement Analysis
• 4.3. Global Artificial Intelligence in Drug Discovery Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
• 4.4. Drug optimization and repurposing
  • 4.4.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
• 4.5. Preclinical testing
  • 4.5.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
• 4.6. Others
  • 4.6.1. Market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 5. Artificial Intelligence in Drug Discovery Market: Therapeutic Area Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Artificial Intelligence in Drug Discovery Market Therapeutic Area Movement Analysis
• 5.3. Global Artificial Intelligence in Drug Discovery Market Size & Trend Analysis, by Therapeutic Area, 2021 to 2033 (USD Million)
• 5.4. Oncology
  • 5.4.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
• 5.5. Neurodegenerative Diseases
  • 5.5.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
• 5.6. Cardiovascular Disease
  • 5.6.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
• 5.7. Metabolic Diseases
  • 5.7.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
• 5.8. Infectious Disease
  • 5.8.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
• 5.9. Others
  • 5.9.1. Market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 6. Artificial Intelligence in Drug Discovery Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Artificial Intelligence in Drug Discovery Market End Use Movement Analysis
• 6.3. Global Artificial Intelligence in Drug Discovery Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
• 6.4. Pharmaceutical & Biotechnology Companies
  • 6.4.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
• 6.5. Contract Research Organizations (CROs)
  • 6.5.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
• 6.6. Academic and Research Institutes
  • 6.6.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
• 6.7. Other
  • 6.7.1. Market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 7. Artificial Intelligence in Drug Discovery Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2025 & 2033
• 7.2. Regional Market Dashboard
• 7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
• 7.4. North America
  • 7.4.1. U.S.
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Regulatory framework
    • 7.4.1.3. Competitive scenario
    • 7.4.1.4. U.S. market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.4.2. Canada
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. Canada market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.4.3. Mexico
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. Mexico market estimates and forecasts, 2021 to 2033 (USD Million)
• 7.5. Europe
  • 7.5.1. UK
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. UK market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.5.2. Germany
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. Germany market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.5.3. France
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. France market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.5.4. Italy
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Italy market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.5.5. Spain
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. Spain market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.5.6. Norway
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. Norway market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.5.7. Sweden
    • 7.5.7.1. Key country dynamics
    • 7.5.7.2. Regulatory framework
    • 7.5.7.3. Competitive scenario
    • 7.5.7.4. Sweden market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.5.8. Denmark
    • 7.5.8.1. Key country dynamics
    • 7.5.8.2. Regulatory framework
    • 7.5.8.3. Competitive scenario
    • 7.5.8.4. Denmark market estimates and forecasts, 2021 to 2033 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Japan
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. Japan market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.6.2. China
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. China market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.6.3. India
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Regulatory framework
    • 7.6.3.3. Competitive scenario
    • 7.6.3.4. India market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.6.4. Australia
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Regulatory framework
    • 7.6.4.3. Competitive scenario
    • 7.6.4.4. Australia market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.6.5. South Korea
    • 7.6.5.1. Key country dynamics
    • 7.6.5.2. Regulatory framework
    • 7.6.5.3. Competitive scenario
    • 7.6.5.4. South Korea market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.6.6. Thailand
    • 7.6.6.1. Key country dynamics
    • 7.6.6.2. Regulatory framework
    • 7.6.6.3. Competitive scenario
    • 7.6.6.4. Thailand market estimates and forecasts, 2021 to 2033 (USD Million)
• 7.7. Latin America
  • 7.7.1. Brazil
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. Brazil market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.7.2. Argentina
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Argentina market estimates and forecasts, 2021 to 2033 (USD Million)
• 7.8. MEA
  • 7.8.1. South Africa
    • 7.8.1.1. Key country dynamics
    • 7.8.1.2. Regulatory framework
    • 7.8.1.3. Competitive scenario
    • 7.8.1.4. South Africa market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.8.2. Saudi Arabia
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Regulatory framework
    • 7.8.2.3. Competitive scenario
    • 7.8.2.4. Saudi Arabia market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.8.3. UAE
    • 7.8.3.1. Key country dynamics
    • 7.8.3.2. Regulatory framework
    • 7.8.3.3. Competitive scenario
    • 7.8.3.4. UAE market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.8.4. Kuwait
    • 7.8.4.1. Key country dynamics
    • 7.8.4.2. Regulatory framework
    • 7.8.4.3. Competitive scenario
    • 7.8.4.4. Kuwait market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company/Competition Categorization
• 8.2. Strategy Mapping
• 8.3. Company Market Position Analysis, 2025
• 8.4. Company Profiles/Listing
  • 8.4.1. Healx
    • 8.4.1.1. Company overview
    • 8.4.1.2. Financial performance
    • 8.4.1.3. Product benchmarking
    • 8.4.1.4. Strategic initiatives
  • 8.4.2. BostonGene Corporation
    • 8.4.2.1. Company overview
    • 8.4.2.2. Financial performance
    • 8.4.2.3. Product benchmarking
    • 8.4.2.4. Strategic initiatives
  • 8.4.3. BenevolentAI
    • 8.4.3.1. Company overview
    • 8.4.3.2. Financial performance
    • 8.4.3.3. Product benchmarking
    • 8.4.3.4. Strategic initiatives
  • 8.4.4. Innophore
    • 8.4.4.1. Company overview
    • 8.4.4.2. Financial performance
    • 8.4.4.3. Product benchmarking
    • 8.4.4.4. Strategic initiatives
  • 8.4.5. Delta4.ai
    • 8.4.5.1. Company overview
    • 8.4.5.2. Financial performance
    • 8.4.5.3. Product benchmarking
    • 8.4.5.4. Strategic initiatives
  • 8.4.6. BioXcel Therapeutics Inc.
    • 8.4.6.1. Company overview
    • 8.4.6.2. Financial performance
    • 8.4.6.3. Product benchmarking
    • 8.4.6.4. Strategic initiatives
  • 8.4.7. BullFrog AI Holdings, Inc.
    • 8.4.7.1. Company overview
    • 8.4.7.2. Financial performance
    • 8.4.7.3. Product benchmarking
    • 8.4.7.4. Strategic initiatives
  • 8.4.8. Graphwise
    • 8.4.8.1. Company overview
    • 8.4.8.2. Financial performance
    • 8.4.8.3. Product benchmarking
    • 8.4.8.4. Strategic initiatives
  • 8.4.9. Owkin, Inc
    • 8.4.9.1. Company overview
    • 8.4.9.2. Financial performance
    • 8.4.9.3. Product benchmarking
    • 8.4.9.4. Strategic initiatives
  • 8.4.10. Insilico Medicine
    • 8.4.10.1. Company overview
    • 8.4.10.2. Financial performance
    • 8.4.10.3. Product benchmarking
    • 8.4.10.4. Strategic initiatives
  • 8.4.11. IBM
    • 8.4.11.1. Company overview
    • 8.4.11.2. Financial performance
    • 8.4.11.3. Product benchmarking
    • 8.4.11.4. Strategic initiatives
  • 8.4.12. Exscientia
    • 8.4.12.1. Company overview
    • 8.4.12.2. Financial performance
    • 8.4.12.3. Product benchmarking
    • 8.4.12.4. Strategic initiatives
  • 8.4.13. Google (DeepMind)
    • 8.4.13.1. Company overview
    • 8.4.13.2. Financial performance
    • 8.4.13.3. Product benchmarking
    • 8.4.13.4. Strategic initiatives
  • 8.4.14. BioSymetrics, Inc.
    • 8.4.14.1. Company overview
    • 8.4.14.2. Financial performance
    • 8.4.14.3. Product benchmarking
    • 8.4.14.4. Strategic initiatives
  • 8.4.15. BPGbio Inc. (Berg Health)
    • 8.4.15.1. Company overview
    • 8.4.15.2. Financial performance
    • 8.4.15.3. Product benchmarking
    • 8.4.15.4. Strategic initiatives
  • 8.4.16. Atomwise Inc.
    • 8.4.16.1. Company overview
    • 8.4.16.2. Financial performance
    • 8.4.16.3. Product benchmarking
    • 8.4.16.4. Strategic initiatives
  • 8.4.17. Recursion
    • 8.4.17.1. Company overview
    • 8.4.17.2. Financial performance
    • 8.4.17.3. Product benchmarking
    • 8.4.17.4. Strategic initiatives
  • 8.4.18. Aitia
    • 8.4.18.1. Company overview
    • 8.4.18.2. Financial performance
    • 8.4.18.3. Product benchmarking
    • 8.4.18.4. Strategic initiatives
  • 8.4.19. Insitro
    • 8.4.19.1. Company overview
    • 8.4.19.2. Financial performance
    • 8.4.19.3. Product benchmarking
    • 8.4.19.4. Strategic initiatives